LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), today presented results at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference showing that elesclomol activity is selective for cancer cells and that continuous, low level infusion of elesclomol demonstrates single agent anti-cancer activity.
